Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trialCorneel Coens, Alexander M.M. Eggermont, Reinhard Dummer et al.|The Lancet Oncology|2017Cited by 104
Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant TherapyStefan Suciu, Marc Buyse, Alexander M.M. Eggermont et al.|JNCI Journal of the National Cancer Institute|2017Cited by 93